Pharmacogenomics: Application to the Management of Cardiovascular Disease
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacogenomics: Application to the Management of Cardiovascular Disease
Authors
Keywords
-
Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 90, Issue 4, Pages 519-531
Publisher
Springer Nature
Online
2011-09-15
DOI
10.1038/clpt.2011.179
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial
- (2012) Benjamin French et al. Trials
- The Missing Association: Sequencing-Based Discovery of Novel SNPs in VKORC1 and CYP2C9 That Affect Warfarin Dose in African Americans
- (2011) M A Perera et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Cardiovascular Pharmacogenomics of Adrenergic Receptor Signaling: Clinical Implications and Future Directions
- (2011) J A Johnson et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy
- (2011) S A Scott et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Heart Failure Pharmacogenetics: Past, Present, and Future
- (2011) Heather M. Davis et al. Current Cardiology Reports
- Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events
- (2010) Klaus A. Tiroch et al. AMERICAN HEART JOURNAL
- Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups
- (2010) N. A. Limdi et al. BLOOD
- Letter by Gurbel et al Regarding Article, “Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement”
- (2010) Paul A. Gurbel et al. CIRCULATION
- Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement
- (2010) Dirk Sibbing et al. CIRCULATION
- Genetic Variation in the β2 Subunit of the Voltage-Gated Calcium Channel and Pharmacogenetic Association With Adverse Cardiovascular Outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES)
- (2010) Yuxin Niu et al. Circulation-Cardiovascular Genetics
- A Polymorphism in the VKORC1 Regulator Calumenin Predicts Higher Warfarin Dose Requirements in African Americans
- (2010) D Voora et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing
- (2010) P Lenzini et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go-DARTS Study
- (2010) L A Donnelly et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans
- (2010) L H Cavallari et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese
- (2010) P.-C. Cha et al. HUMAN MOLECULAR GENETICS
- Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI
- (2010) Jessica L. Mega et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clopidogrel and the Reduced-Function CYP2C19 Genetic Variant
- (2010) Valentin Fuster et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A functional variant of the NEDD4L gene is associated with beneficial treatment response with β-blockers and diuretics in hypertensive patients
- (2010) Patrik Svensson-Färbom et al. JOURNAL OF HYPERTENSION
- Warfarin Genotyping Reduces Hospitalization Rates
- (2010) Robert S. Epstein et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”
- (2010) David R. Holmes et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy
- (2010) D. SIBBING et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
- (2010) Lars Wallentin et al. LANCET
- Clinical assessment incorporating a personal genome
- (2010) Euan A Ashley et al. LANCET
- Effects ofCYP2C19Genotype on Outcomes of Clopidogrel Treatment
- (2010) Guillaume Paré et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis
- (2010) F Sofi et al. PHARMACOGENOMICS JOURNAL
- Individual variability in the disposition of and response to clopidogrel: Pharmacogenomics and beyond
- (2010) Hong-Guang Xie et al. PHARMACOLOGY & THERAPEUTICS
- Adducin- and Ouabain-Related Gene Variants Predict the Antihypertensive Activity of Rostafuroxin, Part 2: Clinical Studies
- (2010) C. Lanzani et al. Science Translational Medicine
- The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention
- (2010) Seok-Jae Hwang et al. THROMBOSIS RESEARCH
- Latent Genetic Backgrounds and Molecular Pathogenesis in Drug-Induced Long-QT Syndrome
- (2009) Hideki Itoh et al. Circulation-Arrhythmia and Electrophysiology
- CACNA1C Gene Polymorphisms, Cardiovascular Disease Outcomes, and Treatment Response
- (2009) Amber L. Beitelshees et al. Circulation-Cardiovascular Genetics
- An α 2C -Adrenergic Receptor Polymorphism Alters the Norepinephrine-Lowering Effects and Therapeutic Response of the β-Blocker Bucindolol in Chronic Heart Failure
- (2009) Michael R. Bristow et al. Circulation-Heart Failure
- Genetic Factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) Are Predictor Variables for Warfarin Response in Very Elderly, Frail Inpatients
- (2009) E Pautas et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin
- (2009) David A Flockhart et al. GENETICS IN MEDICINE
- Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
- (2009) Alan R. Shuldiner JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical and Genetic Modifiers of Long-Term Survival in Heart Failure
- (2009) Sharon Cresci et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side Effects
- (2009) Deepak Voora et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome
- (2009) C. FRÉRE et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M Variant
- (2009) M. G. McDonald et al. MOLECULAR PHARMACOLOGY
- Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
- (2009) NEW ENGLAND JOURNAL OF MEDICINE
- CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population
- (2009) Paola Borgiani et al. PHARMACOGENOMICS
- A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
- (2009) Fumihiko Takeuchi et al. PLoS Genetics
- CYP4F2 genetic variant alters required warfarin dose
- (2008) M. D. Caldwell et al. BLOOD
- A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
- (2008) G. M. Cooper et al. BLOOD
- Pharmacogenetics of aspirin resistance: a comprehensive systematic review
- (2008) Timothy Goodman et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacology and Management of the Vitamin K Antagonists
- (2008) Jack Ansell et al. CHEST
- Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin
- (2008) BF Gage et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- β-Adrenergic Receptor Gene Polymorphisms and β-Blocker Treatment Outcomes in Hypertension
- (2008) MA Pacanowski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Genomic Association Analysis Suggests Chromosome 12 Locus Influencing Antihypertensive Response to Thiazide Diuretic
- (2008) Stephen T. Turner et al. HYPERTENSION
- Physiological Interaction Between α-Adducin and WNK1-NEDD4L Pathways on Sodium-Related Blood Pressure Regulation
- (2008) Paolo Manunta et al. HYPERTENSION
- Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin
- (2008) Martine Gilard et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A GRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failure
- (2008) Stephen B Liggett et al. NATURE MEDICINE
- SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
- (2008) Tabassome Simon et al. NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started